Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.22.2
Stockholders' Equity
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity During the quarter ended June 30, 2022, the Company repurchased 4.2 million shares of Centene common stock for $344 million through the Company’s stock repurchase program. The Company made $106 million in additional purchases under the program in July 2022.In June 2022, the Company's Board of Directors authorized an additional $3,000 million to the Company’s existing stock repurchase program for its common stock, for a total $4,000 million, in preparation for closing of the MagellanRx and PANTHERx divestitures as well as planning for the future. As of June 30, 2022, the Company had a remaining amount of $3,456 million available under the program. The remaining common stock repurchases during the quarter relate to the purchase of shares to satisfy tax withholding requirements in connection with employee equity awards.